Introduction
============

It is well known that the content of sea hare digestive glands is derived from the diet that this animal ingests \[[@b1-marinedrugs-03-00022]--[@b4-marinedrugs-03-00022]\]. A large number of cognate compounds have been isolated from both the red alga of the genus *Laurencia* and the sea hare that preys on the red alga. Metabolites isolated from sea hares exhibit various biological activities, for example, cytotoxic \[[@b5-marinedrugs-03-00022]--[@b7-marinedrugs-03-00022]\], algicidal \[[@b6-marinedrugs-03-00022]\], ichthyotoxic \[[@b8-marinedrugs-03-00022]\], antifungal \[[@b6-marinedrugs-03-00022], [@b8-marinedrugs-03-00022]\], and neurotrophic \[[@b9-marinedrugs-03-00022]\] activities. In the course of our search for new biologically active compounds from marine organisms \[[@b9-marinedrugs-03-00022]--[@b12-marinedrugs-03-00022]\], we succeeded in isolating four compounds exhibiting cytotoxic and antibacterial activities from sea hare collected from Toyama Bay in the Japan Sea. Here we report the isolation, structure determination, and the biological activities of the four compounds including two new derivatives.
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Results and Discussion
======================

Specimens of *Aplysia kurodai* were collected by hand from Toyama Bay in the Japan Sea and kept frozen until extraction with MeOH. The MeOH extract was partitioned between EtOAc and water. The EtOAc layer, which showed cytotoxic and antibacterial activity against *Staphylococcus aureus,* was fractionated by a combination of silica gel chromatography, silica gel HPLC, and gel permeation on Sephadex LH-20 to afford laurinterol acetate (**1**), laurinterol (**2**) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\], debromolaurinterol acetate (**3**), and debromolaurinterol (**4**) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\] in yields of 2.3 × 10^−3^, 3.8 × 10^−3^, 2.6 × 10^−4^, and 3.9 × 10^−4^%, respectively.

The EIMS of **1** showed 1:1 doublet ion peaks at *m/*z 336 and 338 \[M\]^+^, indicating the presence of a bromine atom in the molecule, and a molecular formula of C~17~H~21~O~2~Br was established by HREIMS and ^13^C NMR data. The IR spectrum of **1** showed absorption at 1762 and 1600 cm^−1^, which indicated the presence of a conjugated ester group and an aromatic ring. The ^1^H NMR spectrum of **1** ([Table 1](#t1-marinedrugs-03-00022){ref-type="table"}) revealed two characteristic high-field signals assignable to a trisubstituted cyclopropane ring at δ 0.50 (t, *J* = 4.6 Hz) and 0.55 (dd, *J* = 4.6, 8.8 Hz), two singlet aromatic signals at δ 6.88 (s) and 7.82 (s), four singlet methyls at δ 1.30 (3H, s), 1.34 (3H, s), 2.30 (3H, s), and 2.39 (3H, s). The analysis of COSY and HMBC spectra of **1** suggested the presence of a dimethylbicyclo\[3.1.0\]hexane group and a 1,2,4,5-tetrasubstituted aromatic ring ([Fig. 1](#f1-marinedrugs-03-00022){ref-type="fig"}). The HMBC cross-peak, δ~H~ 1.34 (H~3~-14)/δ~C~ 139.7 (C-6), showed the connection between C-1 of the bicyclohexane ring and C-6 of the aromatic ring. The HMBC cross-peak, δ~H~ 2.39 (H~3~-15)/δ~C~ 136.1 (C-9), revealed the methyl signal was attached to a carbon at C-9, which was supported by the NOE correlation between H~3~-15 and H-8 (δ 6.88, s). The magnitude of carbon chemical shifts of δ 148.3 (C-7) and 121.2 (C-10) indicated that an acetate and a bromine group were substituted at C-7 and C-10, resepectively. These data suggested that **1** was an acetate of laurinterol (**2**) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\]. The acetylation of **2** afforded its monoacetate**,** of which the ^1^H NMR spectrum showed the appearance of an additional acetate signal at δ 2.30 (3H, s) instead of the disappearence of a hydroxy signal at δ 5.39 (s, 7-OH) in **2**. The spectral data of the monoacetate were all identical with those of **1** including the specific rotation, which implied that **1** was laurinterol acetate.

The EI mass spectrum of compound **3** exhibited an ion peak at *m/z* 258 \[M\]^+^, which matched a formula of C~17~H~22~O~2~. The ^1^H NMR spectrum of **3** was similar to that of **1**, except for the presence of two doublet aromatic protons at δ 6.98 (1H, d, *J* = 7.8 Hz, H-10) and 7.57 (1H, d, *J* = 7.8 Hz, H-11) and the absence of a singlet aromatic proton at δ 7.82 (1H, s, H-11) in **1**. These spectral features indicated that **3** was an acetate of debromolaurinterol (**4**) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\]. The acetylation of **4** afforded a monoacetate and its spectral data were identical with those of **3**. Therefore, compound **3** was determined as debromolaurinterol acetate.

The antibacterial activity using *Staphylococcus aureus* ([Table 2](#t2-marinedrugs-03-00022){ref-type="table"}) and cytotoxicity ([Table 3](#t3-marinedrugs-03-00022){ref-type="table"}) were tested for **1**--**4**. Compared with acetates (**1** and **3**) and their original metabolites (**2** and **4**), the latter exhibited more potent antibacterial activity than the acetates. Compounds **1**, **2**, and **4** showed moderate cytotoxicity against HeLa cells.

Conclusion
==========

We have isolated laurinterol acetate (**1**), laurinterol (**2**) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\], debromolaurinterol acetate (**3**), and debromolaurinterol (**4**) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\] from the sea hare, *Aplysia kurodai*. Isolation of **2** and **4** was reported from the red alga, *Laurencia intermedia* Yamada, and their acetates **1** and **3** were derived from **2** and **4** by acetylation, respectively \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\]. However, this is the first isolation of **1** and **3** from natural sources. Among the four metabolites, **1**, **2**, and **4** showed moderate cytotoxicity against tumor cells, and **2** and **4** exhibited more potent antibacterial activity against *Staphylococcus aureus* than **1** and **3**. It is implied that the content of sea hare digestive glands is derived from the red alga of the genus *Laurencia* that this animal ingests \[[@b1-marinedrugs-03-00022]--[@b4-marinedrugs-03-00022]\] and that the metabolites are used for the sake of their self-defense. Although isolation of acetates **1** and **3** from red alga has not been reported so far, the acetates could be derived from the red alga ingested as diet or transformed from **2** and **4** in the digestive gland of the sea hare.

Experimental
============

General
-------

Optical rotations were determined with a HORIBA SEPA-300 high sensitive polarimeter. UV spectra were measured on a Shimadzu UV-1600 UV-visible spectrometer. IR spectra were recorded on a SHIMADZU IR-460 infrared spectrophotometer. NMR spectra were recorded on a JEOL GSX500 in CDCl~3~. All chemical shifts were reported with respect to the residual solvent peaks (δ~H~ 7.26 amd δ~C~ 77.0). Mass spectra were measured on a JEOL SX-102 mass spectrometer.

Extraction and Isolation
------------------------

The frozen material (1.7 kg, wet wt) was extracted with MeOH. The extract was concentrated under reduced pressure and extracted with EtOAc. The EtOAc layer (1.4 g) was subjected to silica gel chromatography with a stepwise gradient of hexane/EtOAc to give two cytotoxic and antibacterial fractions, Fr. 1 (642 mg) eluted with hexane/EtOAc (19:1) and Fr. 2 (354 mg) eluted with hexane/EtOAc (9:1). After purification by silica gel chromatography (hexane/EtOAc) followed by silica gel HPLC (hexane/EtOAc), Fr. 1 gave laurinterol acetate (**1**, 38.7 mg, 2.3 × 10^−3^%) and debromolaurinterol acetate (**3**, 4.5 mg, 2.6 × 10^−4^%). Fr. 2 was purified by silica gel chromatography (hexane/EtOAc) followed by Sephadex LH-20 gel filtration (hexane/EtOAc) to give laurinterol (**2**, 64.8 mg, 3.8 × 10^−3^%) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\] and debromolaurinterol (**4**, 6.8 mg, 3.9 × 10^−4^%) \[[@b13-marinedrugs-03-00022], [@b14-marinedrugs-03-00022]\].

**Laurinterol acetate (1)**: \[α\]^23^~D~ +1.7° (*c* 0.064, CHCl~3~); UV (MeOH) λ~max~ (log ɛ) 269 (3.5) and 279 nm (3.4); IR (film) ν~max~ 3060, 2930, 1762, 1600, 1544, 1482, 1364, 1203 cm^−1;\ 1^H and ^13^C NMR (CDCl~3~), see [Table 1](#t1-marinedrugs-03-00022){ref-type="table"}; EIMS *m/z* 336/338 (intensity, 1:1) \[M\]^+^; HREIMS *m/z* 336.0707(calcd for C~17~H~21~O~2~^79^Br, 336.0725).

**Laurinterol (2)**: ^1^H NMR (CDCl~3~) δ 0.54 (1H, dd, *J* = 8.8, 4.6 Hz, H-12), 0.57 (1H, t, *J* = 4.6 Hz, H-12), 1.13 (1H, dt, *J* = 8.8, 4.6 Hz, H-3), 1.27 (1H, m, H-5), 1.31 (3H, s, H~3~-13), 1.40 (3H, s, H~3~-14), 1.65 (1H, dd, *J* = 13.2, 8.8 Hz, H-4), 1.94 (1H, m, H-4), 2.10 (1H, dd, *J* = 13.2, 8.8 Hz, H-5), 2.28 (3H, s, H~3~-15), 5.39 (1H, br s, 7-OH), 6.61 (1H, s, H-8), 7.60 (1H, s, H-11); EIMS *m/z* 294/296 (intensity, 1:1) \[M\]^+^.

**Debromolaurinterol acetate (3)**: \[α\]^23^~D~ −4.7° (*c* 0.092, CHCl~3~); UV (MeOH) λ~max~ (log ɛ) 265 (3.5) and 275 nm (3.4); IR (film) ν~max~ 2920, 2850, 1730, 1460, 1177, 1038 cm^−1;\ 1^H NMR (CDCl~3~) δ 0.50 (2H, H~2~-2), 1.09 (1H, dt, *J* = 8.8, 4.6 Hz, H-3), 1.28 (1H, m, H-5), 1.30 (3H, s, H~3~-13), 1.34 (3H, s, H~3~-14), 1.65 (1H, dd, *J* = 13.2, 8.8 Hz, H-4), 1.83 (1H, dd, *J* = 13.2, 8.8 Hz, H-5), 1.94 (1H, m, H-4), 2.31 (3H, s, 7-OAc), 2.33 (3H, s, H~3~-15), 6.81 (1H, s, H-8), 6.98 (1H, d, *J* = 7.8 Hz, H-10), 7.57 (1H, d, *J* = 7.8 Hz, H-11); EIMS *m/z* 258 \[M\]^+^; HREIMS *m/z* 258.1625 (calcd for C~17~H~22~O~2~, 258.1620).

**Debromolaurinterol (4)**: ^1^H NMR (CDCl~3~) δ 0.51 (1H, dd, *J* = 7.8, 4.4 Hz, H-12), 0.58 (1H, t, *J* = 4.4 Hz, H-12), 1.13 (1H, dt, *J* = 7.8, 4.4 Hz, H-3), 1.32 (1H, m, H-5), 1.33 (3H, s, H~3~-13), 1.43 (3H, s, H~3~-14), 1.66 (1H, dd, *J* = 13.2, 7.8 Hz, H-4), 1.95 (1H, m, H-4), 2.11 (1H, dd, *J* = 13.2, 7.8 Hz, H-5), 2.27 (3H, s, H~3~-15), 5.05 (1H, br s, 7-OH), 6.55 (1H, s, H-8), 6.68 (1H, d, *J* = 7.8 Hz, H-10), 7.39 (1H, d, *J* = 7.8 Hz, H-11); ^13^C NMR (CDCl~3~) δ 16.6 (C-12), 19.1 (C-13), 20.9 (C-15), 23.9 (C-14), 24.6 (C-3), 25.6 (C-4), 30.0 (C-2), 36.4 (C-5), 48.2 (C-1), 117.6 (C-8), 121.1 (C-10), 129.1 (C-11), 131.7 (C-6), 137.0 (C-9), 154.3 (C-7); EIMS *m/z* 216 \[M\]^+^.

Cytotoxicity Test
-----------------

Cytotoxicity test was carried out with HeLa cells. HeLa cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, penicillin (50 units/mL), and streptomycin (50 μg/mL) under a humidified atmosphere of 5% CO~2~ at 37 °C. The cells were seeded into 96-well microplates (3×10^3^ cells/well) and pre-cultured for a day. The medium was replaced with that containing test compounds at various concentrations and the cells were further cultured at 37 °C for 3 days. The medium was then replaced with 50 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (0.2 mg/mL in medium) and the cells were incubated under the same conditions for 4 h. After addition of 200 μL of DMSO, the optical density at 570 nm was measured with a microplate reader.

Antibacterial Test
------------------

Growth-inhibitory activity was determined by the paper disk method. Paper disk (φ 6 mm) with sample (50, 25, or, 12.5 μg) was incubated on an agar plate containing bacterium at 37 °C.
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###### 

NMR Data for **1** in CDCl~3~.

  no.     δH                        δC      HMBC
  ------- ------------- ----------- ------- ----------------
  1                                 48.0    
  2                                 29.6    
  3       1.10 dt       8.8, 4.6    23.8    
  4       1.66 dd       13.2, 8.8   25.4    C-2
          1.95 m                            
  5       1.26 m                    35.9    
          1.82 dd       13.2, 8.8           C-2, C-14
  6                                 139.7   
  7                                 148.3   
  8       6.88 s                    125.9   C-6, C-10
  9                                 136.1   
  10                                121.2   
  11      7.82 s                    132.5   C-9, C-10
  12      0.50 t        4.6         16.2    
          0.55 dd       8.8, 4.6            
  13      1.30 (3H) s               18.6    C-2, C-12
  14      1.34 (3H) s               23.9    C-2, C-5, C-6
  15      2.39 (3H) s               22.3    C-8, C-9, C-10
  7-OAc   2.30 (3H) s               21.5    7-O*C*OCH3
                                    169.3   

###### 

Growth-Inhibitory Activity of 1--4 against *Staphylococcus aureus.*

  Compd   Inhibitory zone (mm)[a](#tfn1-marinedrugs-03-00022){ref-type="table-fn"}                                                          
  ------- -------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------
  **1**   7                                                                          [b](#tfn2-marinedrugs-03-00022){ref-type="table-fn"}   [b](#tfn2-marinedrugs-03-00022){ref-type="table-fn"}
  **2**   16                                                                         12                                                     7
  **3**   6                                                                          [b](#tfn2-marinedrugs-03-00022){ref-type="table-fn"}   [b](#tfn2-marinedrugs-03-00022){ref-type="table-fn"}
  **4**   10                                                                         8                                                      7

Paper disks (φ 6 mm), impregnated with each sample (50, 25, or, 12.5 μg), were incubated on agar plates containing *Staphylococcus aureus* at 37 °C.

Not tested.

###### 

Cytotoxicity of 1--4 against HeLa cells.

  Compd   IC~50~ (μg/mL)
  ------- ----------------
  **1**   20
  **2**   32
  **3**   \>50
  **4**   18
